HBM Holdings Limited (HKG:2142)

Market Cap	10.95B
Revenue (ttm)	908.35M
Net Income (ttm)	573.61M
Shares Out	838.23M
EPS (ttm)	0.72
PE Ratio	18.06
Forward PE	19.54
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,772,560
Average Volume	5,700,167
Open	13.19
Previous Close	13.06
Day's Range	12.87 - 13.93
52-Week Range	1.12 - 17.98
Beta	1.86
RSI	43.77
Earnings Date	Nov 27, 2025

About HBM Holdings

HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor for tr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 183
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2142

Financial Performance

In 2024, HBM Holdings's revenue was $38.10 million, a decrease of -57.43% compared to the previous year's $89.50 million. Earnings were $2.78 million, a decrease of -87.81%.

Financial numbers in USD